Neuronetics (STIM) Stock Price, News & Analysis

Company Overview

Neuronetics, Inc. (NASDAQ: STIM) is a commercial-stage medical technology company focused on the development and delivery of non-invasive therapies for the treatment of neuropsychiatric disorders. Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics pioneered the use of transcranial magnetic stimulation (TMS) as an alternative to pharmacotherapy for patients suffering from major depressive disorder (MDD). The company’s flagship product, the NeuroStar Advanced Therapy System, has received clearances from the U.S. Food and Drug Administration and has been adopted by healthcare providers seeking to expand access to evidence-based depression treatments.

The NeuroStar Advanced Therapy System delivers targeted, FDA-cleared TMS pulses to regions of the brain implicated in mood regulation, providing an outpatient treatment option for patients who have not responded adequately to at least one antidepressant. Over two decades of clinical research, including more than 200 peer-reviewed publications, have demonstrated NeuroStar’s safety and efficacy in alleviating symptoms of MDD. The company also offers extensive training programs and ongoing clinical support to physicians and clinical staff, ensuring proper protocol adherence and patient management throughout the treatment course.

Neuronetics markets its products primarily in the United States through a dedicated, direct sales force and service network. In addition, the company has established partnerships with distributors and healthcare organizations in select international markets, including Europe, Asia-Pacific and Canada. These collaborations aim to expand the global reach of TMS therapy and foster local education initiatives for mental health professionals. Neuronetics continues to explore opportunities for new indications and markets, leveraging its proprietary TMS platform to address unmet needs in neuropsychiatry.

Under the leadership of President and Chief Executive Officer Sunil Bhonsle, Neuronetics is committed to advancing patient care through innovation in neuromodulation. The company’s executive team brings together expertise in medical device commercialization, neuroscience research and clinical operations. By combining rigorous scientific validation with focused market development, Neuronetics seeks to transform the standard of care for patients with treatment-resistant depression and pave the way for broader applications of TMS technology.

Key Stats

• Today's Range: $3.32 to $3.53
• 50-Day Range: $3.37 to $4.67
• 52-Week Range: $0.52 to $5.92
• Volume: 349,916 shs
• Average Volume: 826,064 shs
• Market Capitalization: $228.41 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.50
• Consensus Rating: Moderate Buy

Neuronetics Stock Analysis - MarketRank™

Neuronetics scored higher than 33% of companies evaluated by MarketBeat, and ranked 737th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neuronetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Neuronetics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neuronetics are expected to grow in the coming year, from ($1.13) to ($0.82) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuronetics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuronetics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuronetics has a P/B Ratio of 6.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.18% of the float of Neuronetics has been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuronetics has recently increased by 13.92%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuronetics does not currently pay a dividend.

Dividend Growth

Neuronetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

5.18% of the float of Neuronetics has been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Neuronetics has recently increased by 13.92%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Neuronetics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neuronetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $826,074.00 in company stock.

Percentage Held by Insiders

Only 8.70% of the stock of Neuronetics is held by insiders.

Percentage Held by Institutions

53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STIM Stock Analysis - Frequently Asked Questions

How have STIM shares performed this year?

Neuronetics' stock was trading at $1.61 at the start of the year. Since then, STIM shares have increased by 114.6% and is now trading at $3.4550.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its quarterly earnings results on Tuesday, May, 6th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by $0.08. The firm had revenue of $31.98 million for the quarter, compared to the consensus estimate of $29.07 million. Neuronetics had a negative net margin of 53.67% and a negative trailing twelve-month return on equity of 174.15%.
Read the conference call transcript.

When did Neuronetics IPO?

Neuronetics (STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair acted as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Top institutional shareholders of Neuronetics include Fermata Advisors LLC (0.02%). Insiders that own company stock include Cannell Capital Llc, Keith J Sullivan, William Andrew Macan, Robert Cascella, Stephen Furlong and Glenn P Muir.
View institutional ownership trends.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK).

Company Calendar

• Last Earnings: 5/06/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:STIM
• CIK: 1227636
• Web: www.neurostar.com
• Phone: (610) 640-4202
• Fax: 610-640-4206
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neuronetics: $5.50
• High Price Target: $8.00
• Low Price Target: $3.00
• Potential Upside/Downside: +57.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$43.71 million
• Net Margins: -53.67%
• Pretax Margin: -54.27%
• Return on Equity: -174.15%
• Return on Assets: -38.41%

Debt

• Debt-to-Equity Ratio: 1.40
• Current Ratio: 2.44
• Quick Ratio: 2.28

Sales & Book Value

• Annual Sales: $74.89 million
• Price / Sales: 3.09
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.57 per share
• Price / Book: 6.14

Miscellaneous

• Outstanding Shares: 66,110,000
• Free Float: 60,362,000
• Market Cap: $231.39 million
• Optionable: Optionable
• Beta: 1.85